Results 41 to 50 of about 1,866 (169)

Impact of Dual Interleukin‐17A and Interleukin‐17F Inhibition With Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: Magnetic Resonance Imaging and Radiographic Outcomes From Two Phase 3 Studies and Their Open‐Label Extension

Arthritis &Rheumatology, EarlyView.
Graphical Abstract Objective To evaluate the impact of bimekizumab, a dual interleukin (IL)‐17A and IL‐17F inhibitor, on sacroiliac joints (SIJ) and spine inflammation/structural damage in axSpA using magnetic resonance imaging (MRI) scans/radiographs from the phase 3 studies BE MOBILE 1 (non‐radiographic axSpA [nr‐axSpA]) and 2 (radiographic axSpA [r ...
Walter P. Maksymowych, Sofia Ramiro, Denis Poddubnyy, Xenofon Baraliakos, Robert G. W. Lambert, Ute Massow, Tom Vaux, Chetan Prajapati, Alexander Marten, Natasha de Peyrecave, Mikkel Østergaard   +10 more
wiley   +1 more source

Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1 year results from two phase 3 studies [PDF]

Objectives: To evaluate 1-year bimekizumab efficacy in psoriatic arthritis (PsA) from the patient perspective using the 12-item PsA Impact of Disease (PsAID-12) questionnaire.
Ogdie, Alexis, de Wit, Maarten, Lambert, Jérémy, Coates, Laura, C, Gossec, Laure, Orbai, Ana-Maria, Taieb, Vanessa, Coarse, Jason, Gladman, Dafna, D, Ink, Barbara   +9 more
core   +1 more source

Bimekizumab for treating active psoriatic arthritis: a single technology appraisal

, 2023
This report is a critique of the company’s submission (CS) to NICE from UCB Pharma on the clinical effectiveness and cost effectiveness of bimekizumab for treating psoriatic arthritis.
Scott, David Alexander, Cooper, Keith, Pickett, Karen, Chinnery, Fay, Picot, Joanna   +4 more
core   +1 more source

Psychometric Validation and Interpretation Thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL©) Questionnaire Using Pooled Data from the Phase 3 BE HEARD I & II Trials of Bimekizumab in Hidradenitis Suppurativa.

British Journal of Dermatology
Background Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition which negatively impacts patients’ physical and mental wellbeing. The HS Quality of Life questionnaire (HiSQOL © ) was developed to assess HS-specific changes in health ...
J. Kirby, L. Thorlacius, Jérémy Lambert, Valerie Ciaravino, Robert L. Rolleri, I. Pansar, Edward Muller, C. Pelligra, J. Ingram   +8 more
semanticscholar   +1 more source

Paradoxical Alopecia Areata Induced by IL‐17 and IL‐23 Inhibitors: A Systematic Review

JEADV Clinical Practice, EarlyView.
This systematic review identifies consistent clinical patterns of alopecia areata associated with IL‐17 and IL‐23 inhibitors, most frequently involving secukinumab and ustekinumab. Disease severity varied widely, and management often required biologic discontinuation or therapeutic switching.
Isabella Kamholtz, Simonetta I. Gaumond, Joaquin J. Jimenez   +2 more
wiley   +1 more source

Therapeutic Challenges in Managing Coexisting Hidradenitis Suppurativa and Squamous Cell Carcinoma: A Clinical Case Study

JEADV Clinical Practice, EarlyView.
ABSTRACT Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder affecting intertriginous areas. Long‐standing HS can undergo malignant transformation into squamous cell carcinoma (SCC), particularly in the perineal and gluteal regions. We report a 54‐year‐old man with severe, treatment‐refractory HS complicated by an aggressive verrucous
Michael Zolotas, Tereza Jakovljevicova, Kamran Ghoreschi, Kerstin Kusch, Marisa Klemp, Robert Sabat, Georgios Kokolakis   +6 more
wiley   +1 more source

Efficacy and Safety of Biologics and Small Molecules for Moderate-to-Severe Hidradenitis Suppurativa: A Systematic Review and Network Meta-Analysis

Pharmaceutics, 2023
Background: Treatment of hidradenitis suppurativa (HS) is difficult and current guidelines are based mainly on expert opinion and non-randomized controlled trials.
Ya-Chu Tsai, Chen-Yiu Hung, Tsen-Fang Tsai   +2 more
doaj   +1 more source

Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years

Journal of Dermatological Treatment
Objectives To investigate the proportion of bimekizumab-treated patients achieving complete clearance in high-impact areas over a four-year period and concurrent patient-reported quality of life outcomes.Methods In this analysis, data are included from ...
Paolo Gisondi, Boni Elewski, Andreas Pinter, Yukie Yamaguchi, Melinda Gooderham, Sarah Kavanagh, Krista Wixted, Nancy Cross, Balint Szilagyi, Joseph F. Merola   +9 more
doaj   +1 more source

Long-Term Effectiveness and Safety of Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa Under Real Clinical Practice Conditions: The Importance of Combined Treatment in Hurley III Patients and Potential Factors Associated with Complete Response

Dermatologic Therapy
Hidradenitis suppurativa (HS) is a debilitating, chronic inflammatory skin disease that severely impacts patients’ quality of life. Bimekizumab, the first dual inhibitor of interleukin (IL)-17A and IL-17F, has shown efficacy in phase 3 clinical trials ...
M. Mansilla-Polo, Carmen García-Moronta, P. Fernández-Crehuet, P. Garbayo-Salmons, M. Pons-Benavent, L. Aguilar-González, D. Jiménez-Gallo, R. Alcalá-García, G. Martin-Ezquerra, Antonio Martorell, L. Mahiques-Santos, F. Alfageme-Roldán, B. Escutia-Muñoz, A. Sahuquillo-Torralba, Rafael Fayos-Gregori, A. Soto-Moreno, Irene Sánchez-Gutiérrez, R. Botella-Estrada, E. Vilarrasa, A. Molina-Leyva   +19 more
semanticscholar   +1 more source

Real World Use of the IL‐36 Receptor Antagonist Spesolimab: A Systematic Review and Analysis

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Spesolimab, an interleukin‐36 receptor antagonist, is approved for the treatment and prevention of generalised pustular psoriasis (GPP) flares. Its use has increasingly been reported in real‐world settings for both GPP and other inflammatory dermatoses.
Sophia A. Mense, Nicole Bavaro, Aashna Farishta, Jiaqi Chen, Raj Chovatiya   +4 more
wiley   +1 more source